Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion

CNBCJune 9, 2026 at 10:13 AM

The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.

This is a summary. For the full story, read the original article at CNBC.

Original source: CNBC

markets

Oracle’s stock has surged on AI hype. Now it has to deliver the earnings to match.

MarketWatchJune 9, 2026 at 11:22 AM

markets

This latest rally may be a dead-cat bounce, warns normally bullish boutique

MarketWatchJune 9, 2026 at 9:20 AM

markets

I’m 60, retired with $3 million. My fiancée, 55, has $1 million but plans to work for the next 10 years. Are we compatible?

MarketWatchJune 9, 2026 at 10:15 AM

← Back to all articles

Related Articles

Oracle’s stock has surged on AI hype. Now it has to deliver the earnings to match.

This latest rally may be a dead-cat bounce, warns normally bullish boutique

I’m 60, retired with $3 million. My fiancée, 55, has $1 million but plans to work for the next 10 years. Are we compatible?